Maze Therapeutics, Inc. – Detailed Financial and Strategic Update for Investors

Ticker: MAZE
Exchange: Nasdaq Stock Market LLC
Fiscal Year Ended: December 31, 2025
Common Shares Outstanding (as of March 20, 2026): 49,708,658
Aggregate Market Value of Public Float (as of June 30, 2025): \$443.9 million (at \$12.27/share)

Key Highlights for Investors

• Emerging Growth Company Status: Maze Therapeutics continues to qualify as an Emerging Growth Company under the JOBS Act, allowing for certain reduced disclosure and regulatory requirements. This status will impact the company’s financial reporting and adoption of new accounting standards.
• Non-Accelerated Filer and Smaller Reporting Company: The company is classified as a non-accelerated filer and a smaller reporting company, which means it is subject to less stringent SEC reporting requirements and may have greater flexibility in its operations and disclosures.
• Well-Known Seasoned Issuer: Maze Therapeutics is designated as a well-known seasoned issuer, which typically allows for streamlined access to capital markets and may support future fundraising efforts.
• Nasdaq Listing & Share Information: The company’s common stock is actively traded on the Nasdaq under the symbol “MAZE.” As of March 20, 2026, there were nearly 50 million shares outstanding, indicating substantial liquidity.
• Strong Public Float: The aggregate market value of common stock held by non-affiliates was approximately \$443.9 million as of the end of June 2025, using the closing price of \$12.27 per share.
• Regulatory Compliance: Maze has filed all reports required under the Securities Exchange Act of 1934 in the past 12 months and has submitted all Interactive Data Files as required. This compliance reduces risk related to regulatory issues.
• Forward-Looking Statements: The company’s annual report contains significant forward-looking guidance regarding its growth plans, financial performance, and market outlook. Investors should be aware these statements are subject to risks and uncertainties, as outlined in the “Risk Factors” section.

Potential Price-Sensitive and Shareholder-Relevant Information

• Risk Disclosure: The company provides a “Summary of Risk Factors” and a detailed “Risk Factors” section. Key risks include the ability to attract and retain key personnel, potential impacts from macroeconomic conditions (such as inflation, interest rates, healthcare policy uncertainty, supply chain delays, banking instability, and labor shortages), and external risks like natural disasters, pandemics, and geopolitical events. Any materialization of these risks could affect the company’s valuation and share price.
• No Restatements or Material Weaknesses: The report indicates that there were no corrections of financial statement errors or restatements requiring compensation clawbacks, and the company is not a shell company. This provides confidence in the accuracy of the company’s financial reporting.
• Financial Reporting: The company’s auditor has not been required to provide an attestation report on internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act. While common for emerging growth and smaller reporting companies, investors should note this as a potential area of additional risk.
• No Other Listed Securities: The only class of securities registered for trading is the common stock; no additional classes or convertible securities are noted as listed.
• Reference to Incorporation of Proxy Statement: Portions of the 2026 Proxy Statement are incorporated by reference into this report, which will provide further details on executive compensation, governance, and shareholder matters. Investors should monitor the upcoming Proxy Statement for additional insights.
• Public Float Calculation: The calculation of the public float excludes shares held by executive officers, directors, and any holder of 10% or more, per SEC rules.

Summary Table of Contents for the 2025 10-K (For Quick Reference)

• Item 1. Business
• Item 1A. Risk Factors
• Item 1C. Cybersecurity
• Item 2. Properties
• Item 3. Legal Proceedings
• Item 4. Mine Safety Disclosures
• Item 5. Market and Stockholder Matters
• Item 7. Management’s Discussion and Analysis (MD&A)
• Item 7A. Market Risk
• Item 8. Financial Statements
• Item 9. Changes in and Disagreements with Accountants
• Item 9B. Other Information
• Item 9C. Disclosure Regarding Foreign Jurisdictions
• Part III (includes details on Directors, Executive Compensation, Security Ownership, etc.)

Forward-Looking Statements and Risk Summary

Maze Therapeutics’ 10-K emphasizes that the company operates in a competitive and rapidly changing environment. The report highlights the unpredictability of risks and notes that actual results may differ materially from forward-looking statements. Investors are strongly encouraged to review the detailed “Risk Factors” section for a comprehensive understanding of uncertainties that could impact the company’s share price and operations.

Disclaimer

This article is provided for informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell securities. Investors should review the full SEC filings and consult their financial advisors before making investment decisions. The information presented is based on the company’s 2025 Annual Report and may be subject to change. No representation or warranty is made as to the completeness or accuracy of the information. Forward-looking statements involve risks and uncertainties, and actual results may differ materially.

View Maze Therapeutics, Inc. Historical chart here